The Saccharomyces cerevisiae genes TORI and TOR2 were originally identified by mutations that confer resistance to the immunosuppressant rapamycin. TOR2 was previously shown to encode an essential 282-kDa phosphatidylinositol kinase (PI kinase) homologue. The TORI gene product is also a large (281 kDa) PI kinase homologue, with 67% identity to TOR2. TORI is not essential, but a TORI TOR2 double disruption uniquely confers a cell cycle (Gi) arrest as does exposure to rapamycin; disruption of TOR2 alone is lethal but does not cause a cell cycle arrest. TOR1-TOR2 and TOR2-TOR1 hybrids indicate that carboxy-terminal domains of TOR1 and TOR2 containing a lipid kinase sequence motif are interchangeable and therefore functionally equivalent; the other portions of TOR1 and TOR2 are not interchangeable. The TORI-I and TOR2-1 mutations, which confer rapamycin resistance, alter the same potential protein kinase C site in the respective protein's lipid kinase domain. Thus, TOR1 and TOR2 are likely similar but not identical, rapamycinsensitive PI kinases possibly regulated by phosphorylation. TOR1 and TOR2 may be components of a novel signal transduction pathway controlling progression through G1.
INTRODUCTION
The immunosuppressive drug rapamycin causes yeast cells and activated T cells to arrest in the Gl phase of the cell cycle Sigal and Dumont, 1992; Schreiber and Crabtree, 1992) . In the yeast Saccharomyces cerevisiae, the three genes FPR1, TORI, and TOR2 are involved in the action of rapamycin. Mutations in any one of these genes renders yeast cells resistant to the toxic effects of the drug (Heitman et al., 1991a) . FPR1 is a nonessential cytosolic FK506-binding protein (FKBP) that also binds the FK506 analogue rapamycin (Heitman et al., 1991b; Koltin et al., 1991; Wiederrecht et al., 1991) . FKBPs are highly conserved, ubiquitous proteins that have proline isomerase activity in vitro and may fold proteins in vivo. TOR2 is an essential phosphatidylinositol kinase (PI kinase) homolog . Cells lacking TOR2 are nonviable * Current address: Preclinical Research, Sandoz, Basel, Switzerland. but arrest randomly in the cell cycle. As described below, TOR1 is a nonessential PI kinase homologue, however, cells lacking both TOR1 and TOR2 arrest in Gl . Thus, the TOR gene products appear to be components of a novel signal transduction pathway that controls progression through the Gl phase of the cell cycle. The current model for drug action is that a FKBPrapamycin complex gains a toxic function that blocks cell proliferation by inhibiting TOR1 and TOR2 .
Phosphatidylinositol (PI) kinases phosphorylate the inositol ring of PI (for review see . PI 4-kinases (type II and III PI kinase) phosphorylate the 4 position of the inositol ring, to produce PI-4-P. PI-4-P is then phosphorylated on the 5 position to produce PI-4,5-P2, which is subsequently cleaved by phospholipase C to form the standard second messengers diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (1P3) (Berridge, 1987; Berridge and Irvine, 1989) .
PI 4-kinase has been detected in various tissues (Hou ) 1994 by The American Society for Cell Biology et Walker et al., 1988; Porter et al., 1989) , and three PI 4-kinases have been purified and characterized from yeast (Buxeda et al., 1991; Nickels et al., 1992; Flanagan and Thomer, 1992) . PI 3-kinase (type I Plkinase) adds phosphate to the 3 position of the inositol ring of PI, PI-4-P, and PI-4,5-P2. In mammalian cells, it appears that at least one of the products of PI 3-kinase, PI-3-P, PI-3,4-P2, and PI-3,4,5-P3, acts directly as a second messenger signaling cell proliferation. First, 3-phosphorylated phosphoinositides are not substrates for phospholipase C (Lips et al., 1989; Serunian et al., 1989) . Second, active PI 3-kinase is associated with activated tyrosine kinases, and in the case of the plateletderived growth factor receptor, PI 3-kinase is an independent downstream mediator of the PDGF mitogenic signal (Cantley et al., 1991; Valius and Kazlauskas, 1993) . Third, the kinetics of appearance of 3-phosphorylated phosphoinositides in PDGF-stimulated cells is consistent with a role as a second messenger . Fourth, the r isozyme of bovine protein kinase C (PKC) can be activated by PI-3,4-P2 and Pl-3,4,5-P3 (Nakanishi et al., 1993) .
In yeast, the ratio of endogenous PI-3-P to PI-4-P is approximately 60:40, in stark contrast to mammalian cells where the ratio is approximately 10:90 (Whitman et al., 1988; Auger et al., 1989a; Stephens et al., 1989; Hawkins et al., 1993) . The yeast PI 3-kinase VPS34 is involved in the sorting of soluble vacuolar proteins. A VPS34 disruption strain is temperature sensitive for growth and exhibits severe defects in the sorting of vacuolar carboxypeptidase Y, and, in addition, has no detectable PI-3-P (Herman and Emr, 1990; Schu et al., 1993) . Thus, in yeast, 3-phosphorylated phosphoinositides have a role in membrane traffic.
The TOR2 gene encodes a 282-kDa protein with homology to the pllO catalytic subunit of bovine phosphatidylinositol 3-kinase and VPS34 (Herman and Emr, 1990; Hiles et al., 1992; . The region of highest homology between the three proteins constitutes a lipid kinase consensus sequence . In the case of VPS34, the lipid kinase motif is required for PI 3-kinase activity .
Here we describe the isolation and characterisation of the TORI gene. The gene is 68 and 67% identical to TOR2 at the nucleotide and predicted amino acid level, respectively, and also contains a so-called lipid kinase domain. Because disruption of TORI and TOR2 individually and disruption of TORI and TOR2 in combination all confer different phenotypes, TOR1 and TOR2 have overlapping and distinct functions. TOR2-TOR1 and TOR1-TOR2 hybrid proteins suggest that a shared cell cycle function is mediated by each intact protein's highly conserved (80% identity) carboxy-terminal lipid kinase domain. Furthermore, the lipid kinase domain of TOR1 and TOR2 may be a target of PKC, as suggested by mutations that confer rapamycin resistance.
MATERIALS AND METHODS Strains, Plasmids and Media
The S. cerevisiae strains used in this work are listed in Table 1 . All strains except the tif2, stel8, and pkcl strains were isogenic JK9-3d derivatives. SH8 was constructed by crossing NB3-3b with NB6-4c and selecting against the pJK3-3 plasmid. YCplacl 11 is CEN4 LEU2 ampr (Gietz and Sugino, 1988 . Plasmid pJK4 is YCplacl 11 containing TOR2 . Plasmid pJK5 is CEN4 URA3 GALlp-TOR2 amp7 (Sherman, 1991) . YPlactate, YPpyruvate, and YPglycerol were prepared as described (Davis et al., 1992) 
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General Genetic Manipulations
Standard genetic techniques of crossing, sporulation, and tetrad analysis were as described (Guthrie and Fink, 1991) . S. cerevisiae transformation was performed by the lithium acetate procedure (Ito et al., 1983) . Escherichia coli strains MH1 or DH5a were used for propagation and isolation of plasmids as described (Sambrook et al., 1989) .
Construction of Genomic DNA Library
Total genomic DNA from the S. cerevisiae strain Ri was isolated as described (Philippsen et al., 1991) and subjected to partial Sau3A digestion. Fragments were fractionated on a 0.8% low-melting agarose gel and ligated into the BamHI site of pSEY18. The ligation mixture was transformed into E. coli strain MH1. Independent transformants (20 000) were pooled and plasmid DNA was isolated. The mean insert size was 12 kb and insert frequency was >80%. The six positive clones isolated from this library were named pPW2, pPW6, pPWl 1, pPW13, pPW14, and pPW15. Subsequently, pPW2 and pPW14 were found to be identical, as were pPW6 and pPW11.
Cloning of TOR1
The TORI-i gene was cloned by using the semidominant rapamycinresistance phenotype conferred by this mutant allele at 30 and 37°C. JK9-3da/a diploid wild-type cells were transformed with the yeast genomic library constructed from the TORI-1 mutant strain R1 in the vector pSEY18. Several genome equivalents of Ura+ transformants selected at 37°C on minimal plates lacking uracil (SD-Ura) were replica plated at 37°C to prewarmed SD-Ura plates containing rapamycin (0.2 Ag/ml). Rapamycin-resistant replica colonies were picked, and the plasmid DNA was isolated (Hoffman and Winston, 1987) . After amplification in E. coli, the plasmid DNA was reintroduced into the original yeast strain JK9-3da/a and plasmid-dependent resistance to rapamycin at 37°C was confirmed on selective plates containing rapamycin (0.2 ,g/ml). To clone the wild-type TORI gene by gap repair (Rothstein, 1991) , plasmid pPW2-13 ( Figure 1A ) was linearized with Bgl II and transformed into the wild-type strain JK9-3da. Plasmids from several independent Ura+ transformants were reisolated and mapped by restriction analysis to confirm the gap repair. For integrative mapping, plasmid pPW2 was linearized at the Bgl II site within the genomic DNA insert and transformed into strain JK9-3da. Ura+ transformants were selected on minimal plates and tested for sensitivity to 5-fluoro-orotic acid, indicative of stable integration of the plasmid.
Integrants were subsequently crossed to strain JH1 1-ic. The resultant diploids were sporulated and meiotic segregants were tested for segregation of the URA3 and TORi-i genes. Rapamycin resistance was used as a marker for the TORI-i allele, and uracil prototrophy was used as a marker for the integrated plasmid. Twenty four tetrads were analyzed.
Mapping the Chromosomal Site of TOR1
The 6.8-kb internal Kpn I fragment of plasmid pPW20 was used as a probe for hybridization to a set of overlapping X-based genomic clones (gift of L. Riles and M. Olson, Washington University, St. Louis). Hybridization was done according to the recommendations of L. Riles. For meiotic mapping, strain Ri (TORI-1) was crossed to strains SS4 (tif2::URA3) and 358/pSTE18 (ste18::LEU2); resultant diploids were sporulated and dissected, and the segregation pattern of URA3 (tif2), LEU2 (ste18), and rapamycin resistance (TORI-1) was followed.
Plasmids for Deletion Analysis
Plasmids for deletion analysis were obtained by cutting plasmid pPW2 (TORI-1) at sites that were present in both the polylinker and in the insert (or multiple times within the insert) and religating. Alternatively, restriction fragments were subcloned into the multi-copy vector YEplacl81, 2,u LEU2 ampr (Gietz and Sugino, 1988) . Plasmids listed in Figure 1A were all derived from plasmid pPW2 (except for pPW15) and represent the following deletions and subclones (there are Sal I, Sph I, Xho I, HindIII and BamHI sites in the polylinker of pSEY18 at the left end of the insert, and Sac I and Kpn I sites in the polylinker at the right end of the insert of pPW2): pPW2-2, ASal I deletion; pPW2-6, ASph I deletion; pPW2-7, AHindIII deletion; pPW2-8, ABamHI deletion; pPW2-9, AXho I deletion of pPW2-2; pPW2-10, ASac I deletion; pPW2-1 1, AXho I deletion; pPW2-12, AKpn I deletion; pPW2-13, ABglII deletion; pPW2-3, the 2.6 kb Kpn I fragment was cloned into pSEY18, which was recut with BamHI (in the polylinker) and Bgl II (within the Kpn I fragment) and ligated with the 9-kb Bgl II fragment of pPW2; pPW2-4, constructed as described for pPW2-3 but starting with the 1-kb HindIII fragment; pPW2-5, the 9-kb Bgl II fragment was inserted into the BamHI site of pSEY18. Plasmids were tested for their ability to confer rapamycin resistance on an otherwise sensitive strain JK9-3da.
TOR1 Disruption
The TORI disruption vector pMD19 was constructed by cutting pPW20 with Sal I and religating (making pPW20-1), followed by replacement of 4 kb and 140 basepair (bp) BamHI fragments with a 2.3-kb Bgl II fragment containing the LEU2 gene. Plasmid pNB6 was constructed in a similar manner, except that a 1.8-kb Bgl II fragment containing the HIS3 gene was used in place of the LEU2 insert. Plasmid pMD18 was constructed by cloning the 4-kb HindIII fragment from pPW20 into pSEY18 and inserting a 2.2-kb Xho I-Sal I fragment containing the LEU2 gene in the unique Xho I site in the insert. Plasmid pMD16 was constructed by cloning the 5.7-kb BamHI fragment from pPW20 into pGEM7Zf(+) (Promega, Madison, Wisconsin) and inserting a 2.2-kb Bgl II ADE2 gene cassette into the unique Bgl II site of the insert. The disruption cassettes were excised from pMD19 (torl::LEU2-4) and pMD18 (torl::LEU2-5) by cutting with Bgl II and HindIII, respectively, and were transformed into JK9-3da/a, selecting for Leu+. The pMD16 disruption cassette (torl ::ADE2-6) was excised with BamHI and transformed into MH272-3fa/a, selecting for Ade+. The pNB6 disruption cassette (torl::HIS3-3) was excised with Bgl II and transformed into MH272-3fa/a, selecting for His'. The successful disruption of the chromosomal TORI locus was verified in transformants by Southern analysis. Diploid strains that showed the expected hybridization pattern were designated MH349 (tori::LEU2-4/TORl), MH350 (tori ::LEU2-5/TOR1), MH353 (torl ::ADE2-6/TORi), and NB6 (torl::H1S3-3/TORi). These strains were sporulated, and 16 tetrads each from strains MH349, MH350, MH353, and NB6 were dissected.
TOR Depletion and Analysis of DNA Content by Flow Cytometry
Haploid strains JK9-3da (TORI TOR2), MH349-3d (torl TOR2), JK350-3a (TORI tor2), and JK350-2a (torl tor2), all containing pJK5 (a CEN4 URA3 plasmid containing TOR2 under control of the GALI promoter) , were grown in liquid SGalGly-Ura medium. Cells were then used to inoculate SD-Ura (glucose) medium at an OD600 of 0.02 and incubated for 16 h at 30°C. In glucose medium, expression of the plasmid-borne TOR2 is repressed and, because TOR2 is essential, TORI tor2 and torl tor2 strains arrested growth in early log phase. The TOR2 cells continued to grow, but were still in log phase when harvested. Three hundred microliters of cells were chilled on ice, sonicated for 2 min in a water bath sonicator, and diluted in 700,l cold absolute ethanol. After shaking overnight at 4°C, the cells were centrifuged briefly, washed once in 50 mM sodium citrate pH 7.4, and resuspended in 500 ttl 50 mM sodium citrate pH 7.4 containing RNase A at 0.25 mg/ml. After incubating 1 h at 37°C, 500 gl of 50 mM sodium citrate, 16 ,tg/ml propidium iodide was added. A BectonDickinson FACScan machine (Lincoln Park, NJ) was used to measure fluorescence, and 10 000 events were analyzed for each strain.
Construction of TOR1-TOR2 and TOR2-TOR1 Hybrid Genes
The pTOR1-TOR2 plasmid was constructed by cutting the vector pJK4 with Sac I and BamHI, and replacing the excised region with a 7.8-Vol. 5, January 1994 S.B. Helliwell et al.
kb Sac I-BamHI fragment of pPW20 containing the promoter and codons 1-1680 of TORI. To obtain the 7.8-kb Sac I-BamHI fragment, pPW20 (pSEY18::TORI) was first cut with Sal I and religated (to remove other Sac I and BamHI sites 3' of the desired region) and then subjected to a Sac I digest, followed by a BamHI partial digest. The partial digest was loaded onto low melting agarose and, after electrophoresis, the relevant band was excised and ligated into the prepared vector as described (Sambrook et al., 1989) . The pTOR2-TOR1 plasmid was made by excising the 4.4-kb BamHI-Sal I fragment from plasmid pJK4 and replacing it with the 4.8-kb BamHI-Sal I fragment from pPW20 containing codons 1681-2470 and the 3'-end of TORI.
DNA Manipulations
Recombinant DNA manipulations were performed according to standard methods (Sambrook et al., 1989) . The DNA probes for Southern analysis were labelled using the random-primed labelling kit (Amersham International, Bucks, UK) following the manufacturer's recommendation. DNA probes for the physical mapping of the TORI gene were made by random-primed 32P-labelling using random hexanucleotides as primers, [a-32P] dATP, and the Klenow fragment of DNA polymerase I. Total yeast genomic DNA for Southern analyses was extracted as described (Guthrie and Fink, 1991) , fractionated by gel electrophoresis on an agarose gel in Tris borate EDTA (TBE) and transferred to nylon membranes. Hybridization was according to the manufacturer's recommendation (Amersham International). For sequencing, restriction fragments were cloned into the vector pGEM7Zf(+) (Promega) and sets of nested deletions were obtained by the exonuclease III method using the Erase-a-Base system (Promega). Custom-made oligonucleotides were used as primers for sequencing regions not accessible with the deletions. DNA sequencing was performed by the dideoxy chain-termination method (Sanger et al., 1977) using the T7 sequencing system from Pharmacia (Piscataway, NJ). To determine the sequence of the TORI-i mutation, a 4.0-kb HindIll fragment containing the region of interest ( Figure 1A ) was cloned into pSEY18 for use as a template. To determine the sequence of the TOR2-1 mutation, a 1.2-kb Sal 1-HindIII fragment of the relevant region was cloned for use as a template.
RESULTS

Isolation of TOR1
The TORI-i mutant allele confers resistance to rapamycin and is semidominant at 30 or 37°C and recessive at 24°C. The TORI gene was isolated using a strategy identical to that used to isolate TOR2 in which the mutant allele was cloned first by taking advantage of the dominant rapamycin resistant phenotype at high temperature. A library was constructed from TORi-i mutant strain Rl in the multicopy vector pSEY18 (2,u URA3) and transformed into JK9-3da/a. Ura+ transformants were selected at 37°C and screened on solid minimal media lacking uracil and containing rapamycin at a concentration of 0.2 ,ug/ml. Plasmids that conferred growth at 37°C on medium containing rapamycin were isolated. Four different plasmids, pPW2, pPW6, pPW13, and pPW15, were obtained from among six that contained overlapping genomic inserts able to confer resistance to rapamycin. Plasmids pPW2 and pPW15 containing the smaller inserts, 16 and 15 kb respectively, were chosen for further characterization. The restriction map of the pPW2 insert and the overlapping region of the pPW15 insert are shown in Figure 1A . pPW15 is denoted in Figure 1A as giving partial resistance (+/-) because transformants with this plasmid did not grow in the presence of rapamycin as well as transformants with the other three plasmids. The insert of pPW2 was shown to correspond to the TORI locus by integrative mapping (see MATERIALS AND METHODS).
The wild-type TORI gene was isolated by gap repair of the cloned mutant allele. Plasmid pPW2-13, pPW2 lacking the internal 9-kb Bgl II fragment ( Figure 1A ), was linearized with Bgl II and transformed into wildtype strain JK9-3d. Plasmids from Ura+ transformants were isolated and amplified in E. coli. A typical recovered plasmid, pPW20, was identical by restriction analysis to pPW2 ( Figure 1A ) but, unlike pPW2, was unable to confer rapamycin resistance. Thus, gap-repaired plasmid pPW20 contained the wild-type TORI allele. This was further confirmed by the subsequent demonstration (see below) that the TORi-i lesion is a single base pair change (Figure 2 ) within the Bgl II fragment deleted for the gap repair.
Physical and Genetic Mapping of TOR1
To determine the map position of TORI, the internal 6.8-kb Kpn I fragment ( Figure 1A ) derived from pPW20 was radiolabeled and used to probe an ordered X-based S. cerevisiae library. Two clones, one corresponding to a position -100 kb centromere-proximal to TIF2 on the left arm of chromosome X and the other corresponding to a position -25 kb centromere-proximal to STE18 on the right arm of the same chromosome, were detected. To further define the map position of TORI, strain Rl (TORI-i) was crossed to strain SS4 (tif2::URA3) and strain 358/pSTE18 (stel8::LEU2). Sporulated diploids were dissected, and segregation of the relevant markers was checked. On the basis of a parental ditype:nonparental ditype:tetratype ratio of 28:0:11, TORI was found to be 14.1 cM centromere-proximal to STE18. No linkage was detected between TORI and TIF2.
TOR1 Is Homologous to TOR2 and PI 3-kinases The position of the TOR1 gene in the 16-kb insert of pPW2 was located by testing the ability of different deletion constructs to confer rapamycin resistance when transformed into a wild-type strain. As illustrated in Figure 1A , an -11-kb region extending from the left most Bgl II site to beyond the right most Kpn I site was required to provide full rapamycin resistance. The nucleotide sequence of this region from plasmid pPW20 containing the wild-type TORI allele was determined. The sequence revealed a 7410 nucleotide open reading frame (ORF) (Figure 2 ) whose ends are in good agreement with the boundaries defined by the deletion analysis. Furthermore, Northern analysis using the internal 4.2-kb HindIII fragment as a probe detected a message of 8 kb that disappeared in a TORI disruption strain. (Figures 3 and 5) . TOR1, like TOR2, is also related to the pllO catalytic subunit of bovine PI 3-kinase and the yeast PI 3-kinase VPS34 (Herman and Emr, 1990; Hiles et al., 1992 . The lipid kinase motif is within amino acids 2123-2296 of TOR1 and amino acids 2127-2300 of TOR2 (Figure 3) . Thus, TOR1 is a PI 3-kinase homologue as is TOR2.
TOR1 contains a Ca2+-dependent lipid-binding (CaLB) domain. The CaLB domain is a sequence motif originally identified as a conserved region in the Ca 2-dependent isozymes of mammalian PKC (a, and 'y) and in phosphoinositidase C, and more recently implicated in the Ca2"-dependent binding of cytosolic phospholipase A2 to membranes (Baker, 1989; Clark et al., 1991 (Clark et al., 1991; Stephens et al., 1993) . The CaLB domain is within amino acids 1522-1629 of TOR1 and in the corresponding position in TOR2 and pllO (Figure 3) . Interestingly, both intracellular Ca2' and the TORs are required for cell cycle progression in yeast (see below) (Iida et al., 1990) .
TOR1 is leucine rich, and the spacing of the leucines in amino acids 312-333 is characteristic of a leucine zipper (Busch and Sassone-Corsi, 1990 ). However, leucine zippers form alpha helices, and a secondary structure prediction based on the algorithms of Kyte and Doolittle (1982) Figure 1B) . Diploids heterozygous for each of the disruptions indicated in Figure 1B were sporulated and dissected. Spores were incubated at 30°C on rich (YPD) medium. Four viable progeny were obtained in each case, indicating that TORI, in contrast to TOR2, is not essential for vegetative growth. The torl segregants grew slightly slower but otherwise behaved like an isogenic wild-type strain. The generation time of torl strains grown in YPD liquid cultures at 30°C was 10-15% longer than that of a wild-type strain. At high and low temperatures this slow growth phenotype was slightly accentuated; at 24°C and 37°C, the generation time of the torl strains was increased 15-25% compared to a wild-type strain (Figure 6, A and B) . This slow growth is not a petite phenotype (respiratory deficiency) because growth on nonfermentable carbon sources (YPglycerol, YPpyruvate, YPlactate) was not altered any more than growth on YPD. The torl mutants also mated normally as assayed by a patch mating assay, and homozygous torl diploids sporulated as well as an isogenic wild-type strain. Furthermore, disruption of TORI did not confer resistance to rapomycin, as expected. No significant differences in behavior among strains containing the different disruption alleles shown in Figure 1B were detected.
Although disruption of TORI alone confers only a subtle growth defect, it confers a very pronounced phenotype when combined with a disruption of TOR2. The TORI TOR2 double disruption causes cells to arrest growth in the Gl phase of the cell cycle as previously determined by a terminal phenotype of large unbudded cells . To characterize further the arrest caused by TOR depletion, we performed flow cytometry (FACS analysis) on a wild-type strain (TOR1 TOR2) and strains lacking TOR1 (torl TOR2), TOR2 (TORI tor2), or both (torl tor2) (see MATERIALS AND METH-ODS). Populations of TORI TOR2, torl TOR2, and TORI tor2 cells exhibited a normal distribution of DNA content, with approximately equal numbers of cells in the Gl (in) and G2/M (2n) phase of the cell cycle ( Figure  4) . The torl tor2 strain showed a DNA distribution typical of cells arrested in the G1 phase of the cell cycle (Figure 4) . Thus, depletion of both TOR1 and TOR2 causes cells to arrest in the Gl phase of the cell cycle, as indicated by a terminal phenotype of large unbudded cells and by a ln DNA content. Further analysis is required to define precisely where in G1 the cells are arrested. The FACS analysis also confirms that strains lacking TOR1 and TOR2 individually do not have an obvious cell cycle defect.
The above results taken together indicate that TOR1 and TOR2 are structurally and functionally related. However, the finding that strains lacking either one of the two TORs have a detectable growth defect suggests that the functions of TOR1 and TOR2 are not completely redundant. Alternatively, growth is stringently controlled by the level of active TOR protein in the cell. 
PI Kinase Controls Cell Cycle Activation
Because rapamycin resistance can be conferred by mutations in FPR1, TORI, or TOR2, we examined whether there is any interplay between disruptions in these three genes. Strain JH3-3b (fprl::URA3-3) was crossed with strains MH349-3d (torl ::LEU2-4) and MH350-la (torl ::LEU2-5). Four viable spores were obtained from the resultant diploids, including segregants with the two disruption markers, indicating that a torl fprl combination is not lethal. Strains MH269-4d and MH272-lc (fprl::URA3-3) were crossed with strain JK350-3a (tor2::ADE2-3) containing a plasmid-bome copy of TOR2 (pJK3-3). Dissection of diploids from which pJK3-3 had been cleared yielded only two viable spores per tetrad. Approximately one-half of the recovered segregants were Ura+ (fprl:: URA3-3), but all were Ade-(TOR2), indicating that fprl cannot suppress the lethality of a TOR2 disruption. Thus, as expected, there appears to be no genetic interaction between FPR1, TORI, and TOR2 disruptions.
The Lipid Kinase Domains of TOR1 and TOR2 Are Interchangeable Our results so far suggest that TOR1 and TOR2 have common and unique functions. To examine the possible differences and similarities in the functions of TOR1 and TOR2 and how these functional differences and similarities might correlate with the structures of the two proteins, we constructed TOR1-TOR2 and TOR2-TOR1 hybrids by gene fusion.
A comparison of overlapping fragments of TOR1 against TOR2 revealed three major peaks of identity corresponding approximately to amino acids 300-1100, 1100-1700, and 1700-2470 ( Figure 5 ). Each peak may represent a functional and structural domain. Because the third domain contains the lipid kinase sequence motif, we constructed the hybrids such that this socalled lipid kinase domain was reciprocally exchanged (Figure 5) . Taking advantage of a conserved BamHI site (Figure 2) to construct the hybrid genes, the promoter region and codons 1-1680 of TORI were fused to codons 1688-2474 and the 3'-end of TOR2 (TOR1-TOR2), and the promoter region and codons 1-1687 of TOR2 were fused to codons 1681-2470 and the 3'-end of TORI (TOR2-TOR1) in low copy number (LEU2 CEN4) plasmids. The plasmid-encoded hybrid proteins were then assayed for TOR1 and TOR2 function by complementation analyses.
To assay for TOR1 and TOR2 function, the hybrid genes were introduced into a torl ::HIS3-3/TOR1 tor2::ADE2-3/TOR2 heterozygous diploid (SH8), and the transformed diploids were then sporulated and dissected. TOR2 function was assayed as follows. Because the tor2::ADE2-3 disruption is lethal, viable Ade+ segregants would be obtained only if a plasmid-borne hybrid gene were present (Leu+) containing the TOR2-TOR1 hybrid (SH8/pTOR2-TOR1) were dissected; 15 Ade+ segregants were obtained, all of which were Leu+, indicating that the TOR2-TOR1 hybrid had TOR2 function. Thirty one tetrads of SH8/pTOR1-TOR2 were dissected; no Ade+ segregants were obtained even though in several cases the plasmid could be inferred to have segregated with Ade+, indicating that the TOR1-TOR2 hybrid did not have TOR2 function (Figure 5 ). TOR1 function was assayed as follows. Because tor2 (tor2: :ADE2-3) segregants undergo three to four rounds of division before arresting growth randomly in the cell cycle and torl tor2 (torl:: HIS3-3 tor2:: ADE2-3) segregants germinate but remain arrested in Gi , we could assay the TOR1-TOR2 hybrid for TOR1 function by monitoring microscopically the segregants of SH8/pTOR1-TOR2 for number of cell divisions and the cell cycle arrest point. Ten segregants of SH8/ pTOR1-TOR2 inferred to be disrupted for both TORI (torl::HIS3-3) and TOR2 (tor2::ADE2-3) and to contain TOR1-TOR2 expressed from the LEU2 CEN4 plasmid (inferred His+ Ade+ Leu+), underwent three to five rounds of division and arrested randomly in the cell cycle. Segregants inferred to be torl tor2 and to lack the hybrid (His' Ade+ Leu-) arrested as single unbudded cells, as expected. Thus, the TOR1-TOR2 hybrid had TOR1 function ( Figure 5 ). We could not assay the TOR2-TOR1 hybrid for TOR1 function in this manner because this hybrid has TOR2 function and the relevant segregants therefore lack only TOR1 that does not prevent growth.
To examine further the hybrids for TOR1 function, we determined whether the hybrids could suppress the slow growth phenotype of a torl mutant. The low copy number (LEU2 CEN4) plasmids bearing the hybrid genes or an intact TOR2 gene were transformed into torl strain MH353-2b (torl::ADE2-6). As shown in Figure 6 , the TOR1-TOR2, TOR2-TOR1, and TOR2 genes could all complement the torl mutation and suppress the slow growth (small colony) phenotype. This suggested that the TOR1-TOR2 hybrid had TOR1 function, as seen previously, and that increased dosage of TOR2, either as a TOR2-TOR1 hybrid or as intact TOR2, could also provide TOR1 function. However, because intact TOR2 can provide TOR1 function in this assay and in a similar assay with a torl tor2 strain, we are hesitant to conclude that TOR2-TOR1 can indeed provide TOR1 function. For reasons that we cannot yet explain, suppression of the slow growth phenotype of a torl mutation with plasmid-borne TOR2 or TOR2-TORI is not a sufficiently sensitive assay to distinguish TOR1 function from TOR2 function. Thus, we were unable to determine with this assay or the one described above whether the TOR2-TOR1 hybrid has TOR1 function.
The above results ( Figure 5 ) indicate that the carboxyterminal lipid kinase domains of TOR1 and TOR2 are interchangeable and therefore functionally equivalent. The lipid kinase domains of TOR1 and TOR2 have a function, as strongly suggested by the consensus sequence, because lesions in these regions abolish TOR activity (Figure 1) . Because the aminoterminal segment and/or upstream regions (promoter and untranslated regions) of each hybrid determines whether it behaves as TOR1 or TOR2, one or both of these elements is not interchangeable and therefore not functionally equivalent.
The TOR1-TOR2 and TOR2-TOR1 Hybrids Are Targets of Rapamycin Because TORI and TOR2 were originally identified by mutations that confer resistance to rapamycin, a shared function of the two proteins is presumably their ability to interact directly with and to be inhibited by FKBPrapamycin. To probe further the structure and function of the hybrids, we examined whether their activity was rapamycin sensitive. torl tor2, TORI tor2, and torl TOR2 segregants of SH8 containing the plasmid-borne TOR2-TORI gene and torl TOR2 segregants of SH8 expressing the TOR1-TOR2 hybrid were sensitive to rapamycin (0.2 ,ug/ml). This sensitivity was indistinguishable from that of a wild-type TORI TOR2 strain. Thus, the hybrids were structurally and functionally intact as targets of FKBP-rapamycin.
The TORl-1 and TOR2-1 Mutations Alter the Same Potential PKC Site in Each Protein's Lipid Kinase Domain To identify the position of the TORI-i mutation, a TOR2-TORI hybrid similar to the one described above was constructed with TORI-i DNA. The TOR2-TORI-1 hybrid conferred rapamycin resistance, unlike the wild-type TOR2-TORI hybrid, indicating that the TORI-I lesion was promoter-distal to the BamHI site ( Figure  2 ) used for construction of the hybrids. To map further the TORi-i mutation, deletion variants and subclones of TORi-i ( Figure 1A ) were assayed for their ability to transfer the TORi-i lesion to a wild-type chromosomal TORI allele by in vivo recombination. Haploid strain JK9-3d transformed with plasmid-borne fragments of TORi-i were incubated on YPD medium containing rapamycin and examined for papillation of rapamycinresistant colonies. The appearance of rapamycin-resistant colonies at high frequency indicated that the plasmid-borne TORi-I fragment being tested contained the lesion and was able to regenerate an intact TORi-i allele. This papillation assay placed the TORI-i mutation domain of TOR1 (TORi-1) or TOR2 (TOR2-1) confers rapamycin resistance. PKC reacts preferentially with serine followed by lysine or arginine in the +1 or +2 position (Kishimoto et al., 1985; Woodgett et al., 1986) .
PKC reacts preferentially with serine followed by lysine or arginine in the +1 or +2 position (Kishimoto et al., 1985; Woodgett et al., 1986) , and mammalian-like PKC isozymes have been described in yeast (Levin et al., 1990; Simon et al., 1991; Riedel et al., 1993) . Because the potential PKC site altered in TORl-1 is also present at the corresponding position in the TOR2 lipid kinase domain (serine,975-arginine) (Figures 3 and   7 ), we examined whether this site is also altered in the rapamycin resistance-conferring TOR2-1 allele (Heitman et al., 1991a) . The sequence of the relevant region of the previously cloned TOR2-1 allele was determined, and the PKC site was indeed found to be mutated. The TOR2-1 allele contains a G to T transversion in the middle position of codon 1975, changing serine,975 to isoleucine. Thus, the TORI-i and TOR2-1 mutations eliminate the same serine in the respective protein's lipid kinase domain; both serines may be phosphorylated by PKC. Interestingly, the TORs and PKCs (mammalian a, ,B and y isozymes) both have a CaLB domain, suggesting that both are translocated to a membrane in a Ca2+-dependent manner.
We examined whether the TORs are in the same pathway as PKC1, a yeast homologue of the Ca2+-dependent isozymes of mammalian PKC (Levin et al., 1990) . Because loss of PKC1 results in a cell lysis defect that is suppressed by osmotic stabilizing agents (Levin et al., 1992) , we first examined whether 1 M sorbitol has any effect on growth of a wild-type strain and TOR mutant strains in the presence and absence of rapamycin. One molar sorbitol had no effect on the sensitivity of a wild-type strain (JK9-3d) or on the resistance of TORl-i (Ri), TOR2-1 (R17), andfprl (JH3-3b) strains to rapamycin (0.2 jig/ml). The lethality of a TOR2 disruption was likewise not affected by 1 M sorbitol; TORI tor2 (JK350-3a) and torl tor2 (JK350-2a) strains containing plasmid-borne TOR2 under control of the GALl promoter (pJK5) failed to grow on glucose media with or without 1 M sorbitol. Growth of a TORI disruption strain (MH349-3d) was also unaltered by 1 M sorbitol. We next examined whether PKC1 disruption or overexpression confers rapamycin resistance. PKCl disruption strain DL164 (Levin et al., 1990) grown in the presence of 1 M sorbitol was sensitive to rapamycin. Strain DL164 containing plasmidborne PKC1 under control of the GALl promoter (pBM743[PKC1]) was also sensitive to rapamycin in the presence of galactose. Thus, PKC1 does not appear to act on TOR1 or TOR2 nor to have a role in a rapamycin sensitive pathway. The TORs may be targets of other more recently described but not yet cloned mammalianlike, Ca2"-dependent PKCs (Simon et al., 1991; Riedel et al., 1993) .
DISCUSSION
The TORI and TOR2 genes of S. cerevisiae were originally identified by mutations that render cells resistant to the immunosuppressant rapamycin. Here we describe the cloning and characterization of TORI. The predicted TOR1 protein is 281 kDa (2470 amino acids) and 67% identical to TOR2 (2474 amino acids). TOR1 and TOR2, in turn, are homologous to the p110 catalytic subunit of bovine PI 3-kinase and the yeast VPS34 PI 3-kinase (Herman and Emr, 1990; Hiles et al., 1992; . All four proteins contain a carboxy-terminal lipid kinase motif. TOR1, TOR2, and pllO contain a CaLB domain (Clark et al., 1991; Stephens et al., 1993) . Disruptions of TORI and TOR2 indicate that either TOR1 or TOR2 is required for progression through the Gl phase of the cell cycle .
Four observations suggest that TOR1 and TOR2 have a common function. First, TORI and TOR2 disruptions are synergistic. Second, both proteins are targets of rapamycin. Third, the two proteins are highly homologous, particularly in the carboxy-terminal lipid kinase domain. Fourth, as observed earlier, specific rapamycin resistance-conferring alleles of TORI and TOR2 do not complement each other (nonallelic noncomplementation) (Heitman et al., 1991a) . Other observations suggest that the common function of TOR1 and TOR2 is a similar, cell cycle-related, rapamycin-sensitive PI kinase activity. First, both a TORI TOR2 double disruption and exposure to rapamycin cause cells to arrest in the G1 phase of the cell cycle. Second, TOR1 and TOR2 are homologous to PI kinases, enzymes frequently implicated in control of the cell cycle. Third, the lipid kinase domains of TOR1 and TOR2 are interchangeable and therefore functionally equivalent. Lastly, mutations that make TOR1 and TOR2 resistant to rapamycin alter a site in the lipid kinase domain of each protein. Thus, the TORs appear to be similar PI kinases, possibly PI 3-kinases, that may signal the cell to transit through G1.
It remains to be determined what type of cell cyclerelated PI kinase TOR1 and TOR2 may be. Although some of the early studies on the physiological role of different phosphorylated phosphoinositides in yeast are difficult to interpret because they predate the discovery of PI 3-kinase (Whitman et al., 1988; Auger et al., 1989a) , several observations have implicated PI 3-kinase, PI 4-kinase, and PI 5-kinase in the control of the yeast cell cycle. Activation of a sterol auxotroph by addition of ergosterol coincides with an increase in PI-4-P (Dahl et al., 1987) . Activation of Gl-arrested yeast cells by addition of glucose correlates with an increase in the levels of PI-4-P and PI-3-P . The synthesis of DAG and IP3 (via PI-4-P) is not stimulated by glucose (Schomerus and Kiintzel, 1992) , but the breakdown of PI-4,5-P2 to DAG and IP3 has been shown to be required for proliferation of yeast cells (Uno et al., 1988) . The lack of detectable PI-3-P in the vacuolar sorting mutant vps34 does not preclude the existence of a cell cycle-related PI 3-kinase . PI 3-kinases other than VPS34 may occur in much lower abundance than VPS34 or may be activated only in response to a specific signal. Furthermore, a cell cyclerelated PI 3-kinase may have a product other than PI-3-P such that the absence of PI-3-P would not be relevant when considering the cell cycle. Hawkins et al. (1993) have detected a molecule in yeast similar to PI-3,4-P2. Three previously identified PI 4-kinases do not necessarily preclude the existence of two more such kinases either (Buxeda et al., 1991; Flanagan and Thorner, 1992; Nickels et al., 1992) . Efforts to determine what type of PI kinase the TORs might be have so far been inconclusive.
Although similar, the two TORs are also different because neither TOR can completely compensate for the loss of the other; disruptions of TORI and TOR2 individually confer different growth defects. The two TORs could be different qualitatively or quantitatively. However, we believe the difference must, at least in part, be qualitative because even increased dosage of TOR1 cannot compensate for loss of TOR2; the TORI gene on a high copy number plasmid cannot rescue a tor2 mutant. Furthermore, TORI and TOR2 mRNA levels are similar and constant throughout the cell cycle (Schneider and Hall, unpublished data) . Qualitative differences between TOR1 and TOR2 could be, for example, differences in regulation (posttranscriptional) or cellular localization. Alternatively, either or both proteins could have a function unrelated to the proteins' presumed PI kinase activity. Because the regions of TORI and TOR2 other than that encoding the lipid kinase domain are not interchangeable, we anticipate that these regions are responsible for the functional difference(s) between TOR1 and TOR2.
The finding that the rapamycin resistance-conferring TORi-i and TOR2-1 mutations alter the same potential PKC site in each protein's lipid kinase domain ( Figure   7 ) has interesting implications with regard to rapamycin action and PI kinase function. Assuming the mutated serine,972 and serine,975 are indeed phosphorylated and loss of the phosphoserine is responsible for rapamycin resistance, two models can be envisaged for drug action.
First, the FKBP-rapamycin complex could inhibit a phosphoserine phosphatase that normally activates TOR by removal of the phosphate from serine1972 in TOR1 and from serine1975 in TOR2. This is similar to the action of the FKBP-FK506 complex in inhibiting the serine/threonine phosphatase calcineurin in yeast and mammalian cells (Liu et al., 1991; Foor et al., 1992; Schreiber, 1992) ; FK506 is a structural analogue of rapamycin and is also an immunosuppressant. Inherent in this model is that TOR activity (presumably PI kinase activity) is negatively regulated by serine phosphorylation, as previously observed for mammalian PI 3-kinase (Carpenter et al., 1993) . However, because TORI-1 or TOR2-1 does not confer a growth defect, TOR is also regulated in some other manner, or a constitutively active TOR does not have a deleterious effect on the cell cycle. According to the second model, FKBP-rapamycin inhibits TOR by binding directly and specifically to the phosphoserine residues in TOR1 and TOR2. This would be analogous to the specific binding of SH2 domains to phosphotyrosine residues in receptor proteintyrosine kinases (Pawson and Schlessinger, 1993) . FKBP-rapamycin may competitively inhibit TOR by preventing the binding of a yet-to-be identified activator molecule that normally binds the TOR phosphoserines. Alternatively, FKBP-rapamycin does not mimic another molecule but simply inhibits TOR noncompetitively. Although we do not yet know whether TOR1 or TOR2 are indeed phosphorylated, both mammalian PI 3-kinase and the yeast PI 3-kinase VPS34 appear to be regulated by phosphorylation. Mammalian PI 3-kinase is serine/threonine and tyrosine phosphorylated. Serine phosphorylation by a tightly associated serine/threonine kinase negatively regulates mammalian PI 3-kinase activity in vitro, and tyrosine phosphorylation likely mediates regulatory interactions with other proteins (Cantley et al., 1991; Carpenter et al., 1993; Kavanaugh et al., 1993; Reif et al., 1993; Stephens et al., 1993) . VPS34 is activated by the associated serine/threonine kinase VPS15 . Should serine1972 of TOR1 and serine1975 of TOR2 not be phosphorylated, the simplest model for rapamycin action is that FKBPrapamycin binds directly to TOR and these serines are important for such an interaction.
Why should yeast have two similar but not identical PI kinases? The yeast cell cycle is activated in response to different and simultaneous environmental cues. Unless nutrients are available and a critical cell size has been attained, a cell remains arrested in Gl. Each of these different signals could be relayed through a different PI kinase. Different PI kinases could thus be required to act in concert for optimal production of a second messenger needed to activate the cell cycle. Although we can only speculate as to the answer to the above question, it is worth noting that there are, also PI Kinase Controls Cell Cycle Activation for unknown reasons, two forms of both the p85 regulatory subunit and the p110 catalytic subunit of PI 3-kinase in mammalian cells Otsu et al., 1991; Hiles et al., 1992; Reif et al., 1993) .
